Novo Nordisk A/S (NVO)
Novo Nordisk A/S (NVO) is a healthcare company (drug manufacturers - general) based in Denmark. The share price is $40.61, down 2.38% on the day, which values the company at $178.98B. Price as of 17 Nov 2026, 17:35 UTC, from Yahoo Finance.
Key facts
- Share price
- $40.61−2.38% today
- Market value
- $178.98B
- P/E ratio
- 10.3×last 12 months
- Forward P/E
- 11.6×
- Dividend yield
- 28.13%
- Funk Score
- 81/100
- 200-week average
- $80.5850% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Novo Nordisk A/S in more detail
NVO trades at 10.3× its last twelve months' earnings, 11.6× next year's expected earnings, 0.5× sales. It sits 50% below its 200-week average of $80.58.
Its Funk Score is 81 out of 100 (financial strength 6.6, profitability 7.7, growth 10.0, each out of 10).
In its favour: Share count keeps falling; High return on invested capital. Worth checking: Debt is growing faster than cash flow; Dividend is not covered by free cash flow.
8 of the superinvestors tracked here hold NVO, including Tom Gayner (0.8% of the portfolio), Lee Ainslie (0.7% of the portfolio), Sarah Ketterer (0.6% of the portfolio).
Superinvestors holding NVO
8 of the investors tracked here report a position in their latest 13F filing.
- Tom Gayner Markel Group0.85% of portfolio · $108.8M · Q3 2026
- Lee Ainslie Maverick Capital0.72% of portfolio · $79.3M · trimmed · Q2 2026
- Sarah Ketterer Causeway Capital Management0.62% of portfolio · $55.3M · trimmed · Q3 2026
- Dodge & Cox team Dodge & Cox0.41% of portfolio · $771.6M · trimmed · Q3 2026
- John Overdeck and David Siegel (founders) Two Sigma Investments0.41% of portfolio · $565.4M · added · Q3 2026
- Jim Simons (1938–2024) Renaissance Technologies0.24% of portfolio · $177.3M · added · Q3 2026
- Charles Brandes (founder) Brandes Investment Partners0.22% of portfolio · $31.5M · new · Q3 2026
- Ken Fisher Fisher Investments0.09% of portfolio · $301.4M · trimmed · Q3 2026
Health Care companies of similar size
- AstraZenecaAZN
- Thermo Fisher ScientificTMO
- AmgenAMGN
- Gilead SciencesGILD
- Abbott LaboratoriesABT
- PfizerPFE
- DanaherDHR
- Intuitive SurgicalISRG
- Vertex PharmaceuticalsVRTX
- MedtronicMDT
- Bristol-Myers SquibbBMY
- StrykerSYK
Side by side:NVO vs ABT (Novo Nordisk A/S vs Abbott Laboratories)NVO vs PFE (Novo Nordisk A/S vs Pfizer)NVO vs DHR (Novo Nordisk A/S vs Danaher)NVO vs ISRG (Novo Nordisk A/S vs Intuitive Surgical)NVO vs GILD (Novo Nordisk A/S vs Gilead Sciences)
All health care companies by market valueLargest companies in DenmarkAll stocks A–Z
Novo Nordisk A/S (NVO): questions and answers
What is NVO's P/E ratio?
Novo Nordisk A/S trades at 10.3× its last twelve months' earnings and 11.6× next year's expected earnings.
What is NVO's PEG ratio?
Novo Nordisk A/S's PEG ratio is 4.31 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Novo Nordisk A/S's market cap?
Novo Nordisk A/S is valued at $178.98B at a share price of $40.61.
Is NVO above its 200-week moving average?
No. NVO is 49.6% below its 200-week average of $80.58. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Novo Nordisk A/S growing?
Over the last three fiscal years Novo Nordisk A/S's revenue grew 20.4% a year and its earnings per share 23.5% a year.
Does NVO pay a dividend?
Yes. Novo Nordisk A/S's dividend yield is 28.13%, or $1.80 a share a year, paying out 45% of earnings.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Novo Nordisk A/S (NVO) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/NVO
Underlying data: Yahoo Finance; company filings with the SEC.